EVENTS:   Best Equity Short Ideas Conference Call 12 - Zach Shannon/Corto Capital Advisors & Craig Huber/Huber Research Partners & Thomas Beevers /Forensic Alpha & Ed Steele/Iron Blue Financials & Bill Campbell/Paragon Intel - 12 Nov 25   Will AI Deflate the World? Macro Lessons from Three Industrial Revolutions and China - Manoj Pradhan/Talking Heads Macro - 13 Nov 25     ROADSHOWS: Forest Products Sector Equity and Commodity Research With Expertise in Distressed Debt - Kevin Mason /ERA Research   •   London   12 - 14 Nov 25       Buyside to Buyside Forum and Expert Calls across TMT, Consumer, Healthcare and Fintech - Andrew Peters /Revelare Partners   •   London   17 - 19 Nov 25       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   17 - 19 Nov 25      

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Atlas Arteria (ALX)

Industrials

Insight Investment Research

Robert Crimes maintains a Sell rating on ALX, citing limited upside vs. broader infrastructure peers and mixed asset quality. While ALX’s stake in APRR delivers robust FCF and steady distribution growth, its minority position and concession expiry in 2035 limit long-term value. The Chicago Skyway deal offers modest value, but DG is deeply value-destructive, with equity estimated 70% below ALX’s 2017 purchase price. ALX's infrastructure distributions are set to rise to A$920m by 2030E but collapse to A$250m in 2037E. Robert expects IFM to increase its stake, but it has had a negative impact on the share price to date and cut daily trading liquidity in half. He continues to prefer Ferrovial (+100% upside) and Getlink (+85%) in Global Toll Roads.

Edition: 212

- 30 May, 2025


Atlas Arteria (ALX)

Industrials

Aequitas Research

Aims to raise ~US$2bn to fund the purchase of its majority interest in Chicago Skyway - ALX’s largest shareholder, IFM (who recently increased their stake to 19.99%) has already publicly stated its opposition for the deal, nonetheless the company has chosen to go ahead with the acquisition. The performance of the shares are likely to be driven more by what IFM does next rather than the company’s fundamentals. The deal scores a negative score on Aequitas’ ECM framework owing to its large size and not being accretive to earnings in the near term - this is one to avoid for new shareholders even at the entitlement offer price.

Edition: 144

- 16 September, 2022